EMA data disclosure policy needs a rethink, says industry
This article was originally published in Scrip
Comments submitted by the European industry federation EFPIA give some indication of the challenges facing the European Medicines Agency if it is to finalise and implement its new policy on the publication of clinical trial data by the 1 January 2014 deadline.
You may also be interested in...
The UK government says it will begin a consultation on a future falsified medicines scheme for Great Britain within a year after the passage of new legislation on medicines and medical devices. Moves are also under way to ensure the smooth supply of medicines from GB to Cyprus, Ireland, Malta and Northern Ireland.
The team behind Russia’s first COVID-19 vaccine has asked for scientific advice from EU drug regulators in view of a possible submission for marketing authorization.
The number of new drugs containing new active substances approved in the EU rose significantly in 2020, underpinned by a strong showing for orphan-designated products and a string of novel medicines for cancer and infectious diseases. Notable among the new clutch of approvals was the first ever COVID-19 vaccine, Pfizer/BioNTech's Comirnaty.